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Abstract Murine N9 microglia accumulated AL from media
containing 0.67 WM AL within 6 h. In N9 and in primary rat
microglia, chloroquine, which disrupts lysosomal pH, increased
AL-induced accumulation of AL, particularly AL1^42. Leupeptin
similarly enhanced AL accumulation. The scavenger receptor
antagonist fucoidan did not affect acute chloroquine-dependent
AL1^42 accumulation, demonstrating uptake of non-aggregated
AL. After prolonged incubations, chloroquine enhanced AL
multimer (8^12 kDa) accumulation, an effect inhibited by
fucoidan. Disruptions of the lysosomal system enhance AL and
its multimer formation. Despite negligible effects of fucoidan on
initial AL uptake, chronic exposure inhibits multimer accumula-
tion, demonstrating a role for scavenger receptor in multimer
accumulation.
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1. Introduction
A pathological hallmark of Alzheimer’s disease (AD) is the
cerebral deposition of amyloid plaques which arise from the
abnormal accumulation of amyloid L-protein (AL). AL pep-
tides are 40^43 amino acid proteolytic fragments excised from
L-amyloid precursor protein (L-APP). Compelling genetic evi-
dence has indicated that over-production of AL, especially
AL1^42, can be an ultimate cause of neurodegeneration.
Among cases of early-onset familial Alzheimer’s disease
(FAD), an autosomal dominant disorder, mutations are
found in multiple genes [1,2]. These mutations increase either
the production of AL or the proportion of the more insoluble
AL1^42 fragments. In contrast, APP mutations and systemic
AL over-production are not found in the late-onset, sporadic
form of AD (SAD) [1] which accounts for the vast majority
(s 90%) of AD cases. Therefore, factors such as decreased
cellular degradation of AL peptide or aggregates, reduced
AL phagocytosis, and enhanced stabilization of AL ¢brils
may be particularly relevant to AL accumulation in SAD.
AL is secreted by brain cells under normal conditions [3,4],
but its level remains low in CSF and plaque-free brains of
healthy controls [5]. Therefore, a catabolic process must exist
in which protease(s) degrade the peptide to prevent its accu-
mulation. A major di¡erence between an aging AD brain and
a healthy counterpart could be defective catabolism which
results in AL accumulation and deposition.
Cellular uptake and intracellular degradation are poten-
tially important pathways for the removal of extracellular
AL. PC12 cells were able to e¡ectively internalize AL and
accumulate AL1^42 speci¢cally for several days [6]. Ida et
al. [7] demonstrated the rapid AL uptake by human neuro-
blastoma SY5Y cells which removed the majority of exoge-
nous AL by uptake and intracellular degradation rather than
by extracellular proteases. However, these cells do not resem-
ble the activated microglia and reactive astrocytes intimately
associated with dense core amyloid plaques in AD brain [8].
Both rat microglia and astrocytes can remove AL1^42 added
to culture medium [9]. After subjecting rat primary microglia
to subcellular fractionation, Mentlein et al. [10] recently
showed that an AL-degrading activity was primarily mediated
by a metalloprotease released into the extracellular medium.
Other studies have shown that rat microglia are able to accu-
mulate AL peptides [11] and aggregates [12], suggesting that
intracellular degradation via the endosomal-lysosomal system
is important for AL removal. Both APP and APP C-terminal
fragments are known to be metabolized by the endosomal-
lysosomal system [4,13^15]. Furthermore, lysosomal proteases
such as cathepsins B (cysteine protease) and D (aspartyl pro-
tease) are associated with AD amyloid deposits [16,17]. The
presence of these lysosomal enzymes in the amyloid plaques
may re£ect an attempt to degrade AL. To test whether micro-
glia degrade AL intracellularly, we examined the accumulation
and degradation of added AL1^40 and 1^42 in the N9 murine
microglia cell line. A signi¢cant amount of undegraded AL,
especially AL1^42, was found inside the cells with chloroquine
and leupeptin, compounds which inhibit lysosomal enzyme
activities.
2. Materials and methods
2.1. Sandwich ELISA for AL
Cellular AL was quanti¢ed with a sandwich ELISA utilizing two
AL peptide-speci¢c antibodies. Mouse monoclonal 4G8 against AL aa
17^24 (Senetek, Maryland Heights, MO) was used as the capture
antibody, loaded at a concentration of 3 Wg/ml in 0.1 M carbonate
bu¡er, pH 9.6 onto a 96-well plate (Nunc Maxisorp). Blocking was
completed with 2% bovine serum albumin (BSA) in Tris-bu¡ered
saline (TBS). Processed and neutralized samples were diluted with
EC bu¡er (20 mM Tris, 400 mM NaCl and 2 mM EDTA, pH 7.4
with 1% BSA and 0.05% CHAPS) containing protease inhibitors
(20 Wg/ml each of pepstatin, aprotinin, leupeptin, and phosphorami-
don, 0.5 mM PMSF and 1 mM EGTA) and loaded into the wells. The
detector antibody was biotinylated mouse monoclonal 10G4 against
AL aa 5^13 [18], added at a ¢nal dilution of 1:1500 in TBS containing
1% BSA. The reporter system was streptavidin-alkaline phosphatase
(Vector Labs, Burlingame, CA) using AttoPhos (JBL, San Luis Obis-
po, CA) as the substrate. Fluorescence of the AttoPhos product was
monitored at an excitation wavelength of 450 nm and an emission
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wavelength of 580 nm with a CytoFluor II plate reader (PerSeptive
Biosystems, Bedford, MA). A standard curve over a range of 0.02^
10 ng (Fig. 3A) was prepared from AL peptide in triplicate and sub-
jected to 4-parameter ¢t by non-linear regression. Statistical ANOVA
was used to evaluate treatment e¡ects and Fisher’s projected of least
signi¢cant di¡erence (PLSD) was used to detect di¡erences between
groups (Statview, Abacus, Berkeley, CA).
2.2. Cell culture
N9 microglia (a mouse microglia cell line, a generous gift from Dr.
P. Ricciardi-Castagnoli) [19] were grown in Dulbecco’s modi¢ed Ea-
gle’s medium (DMEM) with high glucose and supplemented with 10%
fetal calf serum, L-glutamine, non-essential amino acids, sodium pyr-
uvate, HEPES bu¡er, and gentamicin sulfate. Cells were cultured in
75 cm2 £asks and passaged without trypsin using cell dissociation
bu¡er (Sigma, St. Louis, MO). They were subcultured into 24-well
plates at 80% con£uency or Nunc 8-chamber Labtek slides at
5000/well 1 day before the experiment. For primary mixed glia cul-
ture, cerebral hemispheres from 2 day old Sprague-Dawley rat pups
were excised and the meninges removed. The hemispheres were ¢ltered
successively through 210, 185, and 136 Wm nylon meshes into DMEM
with the same supplements described above. The cell suspension
was centrifuged and resuspended in media before seeding 106 cells
to a 75 cm2 £ask. Primary cultures were incubated for 5 days before
use.
2.3. Analysis of intracellular AL after cellular uptake
Con£uent N9 microglia in a 24-well plate were washed once with
phosphate-bu¡ered saline (PBS) and once with N2 medium (serum
free) before exposure to 300 Wl of N2 medium containing 1 Wg
(0.67 WM) of AL, with and without chloroquine or leupeptin. Cells
were incubated with the drug(s) for 6 h in the CO2 incubator with
gentle shaking. At the end, the medium was removed and the cells
washed twice with PBS before trypsinization which removed cell
membrane associated AL. After a centrifugation at 1000Ug for
10 min, the cell pellet was washed once with PBS and stored at
320‡C until assay of AL. On the day of analysis, cell pellets were
solubilized in 70% formic acid. Acid extract was neutralized with 70%
0.25 M Tris, pH 8/30% acetonitrile and 5 M NaOH before loading
onto the ELISA plate. Total cell protein was measured by the Bio-
Rad Dc (Hercules, CA) Lowry assay using BSA as a standard.
2.4. Immuno£uorescent labeling of intracellular AL
N9 microglia grown on 8-chamber Labtek slides were exposed to
1 Wg of AL, with or without 20 WM chloroquine, for 6 h. At the end,
the cells were washed 3 times with cold PBS and ¢xed with cold
methanol at 4‡C for 10 min, then methanol was removed and cells
washed 3 times with cold PBS. After blocking with 5% horse serum at
37‡C for 1 h, cells were incubated with mouse monoclonal 4G8
(1:100) at RT for 1 h. Bound 1‡ antibodies were detected with horse
anti-mouse IgG (2‡ antibody, 1:200) coupled to FITC and photo-
graphed using a Microphot £uorescence microscope (Nikon).
All images were acquired as TIFF ¢les from a £uorescent micro-
scope via a video camera attached to a Scion frame grabber, which
were subsequently analyzed on a Power Center 120 Macintosh com-
patible computer using a NIH-Image public domain software (devel-
oped at the US National Institutes of Health and available on the
Internet at http://rsb.info.nih.gov/nih-image/). A custom Pascal macro
sub-routine was written to calculate £uorescent intensity relative to
background (foreground3background/background) and total % AL-ir
area.
2.5. Western blotting
Equal amounts of protein from the cell pellets were mixed with
Laemmli’s sample bu¡er and heat-denatured before being loaded
onto 8^16% Tris Tricine gel with rainbow standards (Amersham,
Piscataway, NJ) as molecular weight reference. Separated proteins
were blotted onto nitrocellulose membrane and detected with sequen-
tial incubation with mouse monoclonal 10G4 1‡ antibodies (1:750),
goat HRP-conjugated anti-mouse IgG 2‡ antibodies (1:5000) and sub-
saturating ECL solution (Amersham).
3. Results
3.1. E¡ects of chloroquine on intracellular AL level quanti¢ed
by sandwich ELISA
As the cells were trypsinized to remove membrane-associ-
ated AL, any detectable signal in the ELISA must have origi-
nated from the intracellular compartment. When N9 micro-
glia were exposed to 1 Wg (0.67 WM) of AL (1^40 or 1^42)
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Fig. 1. Immuno£uorescent staining of AL1^42 with and without chloroquine (CHQ, 20 WM). Cell-associated AL was detected by mouse mono-
clonal 4G8 (1‡ antibody) followed by horse anti-mouse IgG (2‡ antibody) coupled to FITC and visualized under the £uorescence microscope.
N9 microglia were incubated with (A) vehicle, (B) CHQ, (C) AL1^42 (arrows indicate selected isolated cells that are actively taking up AL),
and (D) CHQ+AL1^42. Bar = 80 Wm.
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alone for 6 h, AL1^42 preferentially accumulated intracellu-
larly while the level of AL1^40 was non-detectable (Fig. 3B).
The intracellular level of undegraded AL, especially that of
AL1^42, increased substantially in the presence of chloro-
quine, a weak base that disrupts lysosomal functions [20] by
dissipating the transmembrane pH gradient (Fig. 3B). Intra-
cellular AL1^40 was detected only in the presence of higher
chloroquine concentrations (40 and 125 WM), but its level was
still lower than that of AL1^42. There was no gross loss of
viability upon 6 h chloroquine incubation as LDH release was
similar in both control and treated cells (data not shown). The
chloroquine-dependent accumulation of AL1^42 after 6 h in
N9 microglia was also seen in primary rat microglia which
accumulated 0.2075 þ 0.0275 ng of AL1^42/mg protein in the
absence of chloroquine and 0.3175 þ 0.012 ng AL1^42/mg pro-
tein in the presence of 40 WM chloroquine (P6 0.05, signi¢-
cantly di¡erent from AL only). Chloroquine alone (without
exogenous AL) may also enhance accumulation of endoge-
nous AL as demonstrated by a consistent, although faint pat-
tern of intracellular AL-ir punctate labeling in the Fig. 1B
micrograph, a pattern not visualized in other treatment
groups. However, quantitative analysis of cells (both N9
and primary rat microglia cells) treated with chloroquine
alone (40 or 125 WM) was not sensitive enough to pick up
the di¡erence between controls and chloroquine alone. In ad-
dition, AL-bearing C-terminal fragments of APP are also pro-
duced and processed in the endosomal/lysosomal compart-
ment [4]. Thus, chloroquine may cause an accumulation of
endogenous C-terminal fragments by interfering with their
lysosomal degradation. The sandwich ELISA was speci¢c
for AL since 10G4 fails to detect APP (data not shown).
The absence of any ELISA immunoreactivity in cells treated
with chloroquine alone indicated that C-terminal fragments
are not detected in ELISA.
3.2. E¡ect of chloroquine on cell-associated AL revealed by
immuno£uorescent labeling
In order to con¢rm that chloroquine treatment increases
cellular AL, we measured AL-immunoreactive £uorescence
(ir) using anti-AL (4G8) after 6 h incubation (Fig. 1). No
AL-ir was observed in control cells with no treatment (Fig.
1A) or in cells untreated with primary antibody (not shown).
Chloroquine alone induced a characteristic punctate intracel-
lular AL-ir labeling (Fig. 1B), but this did not result in quan-
titative di¡erences in total £uorescence intensity or % AL-ir
area (Fig. 2). AL1^42 (Fig. 1C) induced what appeared to be
clusters of cells with both surface labeling and some perinu-
clear labeling. Addition of chloroquine to AL1^42-treated
cells resulted in a dramatic upregulation of AL-ir, which was
predominantly perinuclear. Addition of AL1^40 alone or in
conjunction with chloroquine resulted in similar but less pro-
nounced e¡ects compared to AL1^42 (not shown).
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Fig. 2. Image analysis of cells treated with AL42 with or without
chloroquine (CHQ). Data show % AL-ir area (black) and £uores-
cent intensity (gray) in arbitrary units as relative OD (foreground3
background/background). CHQ+AL42 showed more area stained as
well as higher intensity than AL42 alone (P6 0.05), and values from
both these treatments were signi¢cantly greater than CHQ or AL42
alone (P6 0.05). CHQ or AL42 alone were not signi¢cantly di¡erent
from each other.
Fig. 3. A: A typical ELISA standard curve with 4-parameter ¢t by non-linear regression, r2 = 0.994 and the lowest detection limit is 10 pg in
our experiments. B^D: N9 microglial cells were treated with 1 Wg of AL1^40 or 1^42 and cells harvested at 6 h. Cells were harvested and AL
in the cell pellet measured by sandwich ELISA. B: Dose-dependent e¡ect of chloroquine (CHQ) on intracellular AL (1^40 and 1^42) accumula-
tion. C: Dose-dependent e¡ect of fucoidan on intracellular AL1^42 accumulation. D: Dose-dependent e¡ect of leupeptin on intracellular AL1^
42 accumulation. The level of intracellular AL at 30 WM leupeptin was signi¢cantly di¡erent from that of 100 WM leupeptin (P6 0.05). Values
are means þ S.D. of triplicates. *Signi¢cantly di¡erent from cells with no chloroquine treatment, P6 0.05. ND: non-detectable.
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3.3. E¡ect of fucoidan on intracellular AL1^42 accumulation
Fucoidan is a polyanionic antagonist for the type A scav-
enger receptors expressed by macrophages. In a previous
study, 10 or 500 Wg/ml of fucoidan e¡ectively blocked the
uptake of AL microaggregates which showed that they were
mainly internalized via the scavenger receptor [12]. To test a
possible role of this receptor on N9 uptake of AL, cells were
incubated with AL1^42 (1 Wg) and chloroquine (40 WM) to-
gether, with or without the fucoidan (50 and 400 Wg/ml). After
a 6 h incubation, fucoidan had no e¡ect on the accumulation
of intracellular AL (Fig. 3C). Therefore, the AL species being
internalized by N9 within 6 h were mostly non-aggregated and
soluble, consistent with successful initial solubilization of the
applied AL. This suggests that in this paradigm, an alternative
pathway to the scavenger receptor is being used for AL up-
take.
3.4. E¡ect of leupeptin on intracellular AL1^42 degradation
Leupeptin is a moderate cell-permeable inhibitor for lyso-
somal cysteine proteases including cathepsins B, H and L [21].
When N9 microglia were incubated with AL1^42 (1 Wg) and
leupeptin (30 and 100 WM) for 6 h, intracellular AL1^42 levels
increased substantially when compared to cells exposed to AL
1^42 alone (Fig. 3D; ND: non-detectable under the experi-
mental conditions). Increasing the concentration of leupeptin
to 500 WM appeared to increase AL1^42 accumulation com-
pared to 100 WM of leupeptin but the di¡erence was not
statistically signi¢cant. Incubation of cells with leupeptin
alone (100 WM) resulted in no detectable AL signal (data
not shown).
3.5. E¡ect of chloroquine and fucoidan on accumulation of AL
multimers (8^12 kDa)
To examine the e¡ect of chloroquine on long-term AL dis-
position, cells were incubated with AL and a low concentra-
tion of chloroquine (20 WM) for 24 h. Both trypsinized and
non-trypsinized cell pellets were subjected to Western blot
analysis. Monomeric AL (4 kDa) was not detected under
our Western blot conditions but multimeric AL (between 6
and 14 kDa) was found in both trypsinized and non-trypsi-
nized cells. At 24 h, there is a signi¢cant amount of multi-
meric AL in AL-treated cells without trypsinization (Fig. 4A,
lane 2) and chloroquine co-treatment markedly increased
these cell-associated AL multimers (lane 3). A similar phe-
nomenon was also observed in trypsinized cells (Fig. 4B)
when 20 WM of chloroquine e¡ectively augmented intracellu-
lar AL multimer accumulation (lanes 5 and 6), compared to
AL alone (lanes 1 and 2) and 5 WM chloroquine (lanes 3 and
4). Interestingly, with the 24 h sample (in contrast to the 6 h
sample analyzed by ELISA), fucoidan (400 Wg/ml) reversed
the e¡ect of chloroquine on AL multimer accumulation (Fig.
4B, lanes 5 and 6 vs. 7 and 8) by decreasing the amount to a
level lower than that from cells exposed to AL only. The AL
multimer was not detected in either trypsinized or non-trypsi-
nized cells upon incubation with AL for only 6 h, with and
without chloroquine (data not shown).
4. Discussion
Characterization of AD amyloid deposits has indicated that
AL1^42 is a major component pertinent to pathogenesis and
is the initially-deposited species [22,23]. The unique behavior
and physical properties of AL1^42 could account for its role
in plaque evolution. Accordingly, Ard et al. [11] have demon-
strated that exogenous AL1^42 was accumulated largely in the
lysosomes. By using peripheral cells such as human ¢broblasts
[24] and rat PC12 cells [6], intracellular AL1^42 has been
shown to remain in the lysosomes and co-localize with lyso-
somal markers such as lucifer yellow and horseradish peroxi-
dase. These authors used a relatively high, aggregate-forming
concentration (25 WM) of radioactive AL to show that AL1^42
was more resistant to degradation than AL1^40. To better
mimic physiological concentrations, we have chosen lower
concentrations (0.67 WM) of AL and found preferential accu-
mulation of AL1^42 with both ELISA (Fig. 3B) and immuno-
£uorescent labeling speci¢c for AL (Figs. 1 and 2). No pref-
erential accumulation of AL1^40 occurs as detected by
ELISA. In this system, immuno£uorescence showed that min-
imal AL1^40 may be accumulating, but it may be primarily
cell surface-associated AL, which would be degraded by tryp-
sin in the ELISA sample preparation. Burdick et al. [6] have
suggested that AL1^42 accumulation could be due to its pref-
erential adsorption (over AL1^40) to the cell surface and,
thus, its preferential internalization. We believe that ine⁄cient
degradation of AL1^42 could also account for its selective
accumulation because its level was signi¢cantly increased
when the pH-dependent activities of the lysosomal enzymes
were compromised by chloroquine [20]. The ine¡ective degra-
dation and lysosomal accumulation can be attributed to the
aggregation properties of AL1^42 [25]. Since AL1^42 tends to
accumulate in the lysosomes, it may be more prone to lyso-
somal changes than AL1^40. Even without chloroquine, cer-
tain isolated cells accumulated abundant AL1^42, while others
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Fig. 4. A: Immunoblot of AL1^42 in non-trypsinized cell pellet after
24 h incubation. Lane 1: control; lane 2: 1 Wg AL ; lane 3: 1 Wg
AL+20 WM chloroquine; lane 4: 1 Wg AL+20 WM chloroquine+400
Wg/ml fucoidan. The positions of the 6 and 14 kDa molecular
weight markers are shown. B: Immunoblot of AL1^42 in trypsinized
cell pellet after 24-h in ubation. Lanes 1 and 2: 1 Wg AL ; lanes 3
and 4: 1 Wg AL+5 WM chloroquine; lanes 5 and 6: 1 Wg AL+20
WM chloroquine; lanes 7 and 8: 1 Wg AL+20 WM chloroquine+400
Wg/ml fucoidan.
T. Chu et al./FEBS Letters 436 (1998) 439^444442
accumulated none, suggesting that cells that begin to accumu-
late AL activate an autocrine positive feedback loop for more
accumulation. Such an auto-catalytic process may involve up-
regulation of a receptor or AL1^42-induced lysosomal dam-
age.
Microglia cells can accumulate pre-aggregated AL from me-
dia via the scavenger receptor [12]. Blockade of this receptor
by fucoidan, however, did not alter the acute, intracellular
level of AL1^42 in the presence of chloroquine (Fig. 3C),
demonstrating an alternate pathway for AL uptake. Thus,
the AL being internalized is mostly soluble and non-aggre-
gated when present at low concentration (0.67 WM) in the
medium for 6 h. The absence of AL multimers at 6 h further
supports this hypothesis. Multimers were only detected with
long exposures (24 h) to AL. In contrast to the pre-formed AL
microaggregates described by Paresce [26], which are largely
undegraded 72 h after uptake, the 8^12 kDa AL is rapidly
degraded in the absence of chloroquine. Chloroquine notably
increased the amount of cell-associated (Fig. 4A) and intra-
cellular AL multimers (Fig. 4B). These data show that micro-
glia cells, aside from accumulating pre-formed AL aggregates
[11], can also accumulate soluble AL and may possibly pro-
vide a cellular micro-compartment for aggregate and multimer
formation over time. Despite negligible e¡ects of fucoidan on
initial AL uptake, chronic exposure inhibits 8^12 kDa AL
accumulation, demonstrating a probable role for scavenger
receptor on multimer accumulation.
Despite the lack of e¡ect of fucoidan on chloroquine-de-
pendent AL accumulation by ELISA, fucoidan clearly attenu-
ated the chloroquine-induced AL multimer accumulation.
These seemingly con£icting results may relate to the facts
that (1) microglia are regurgitating undegraded, intracellu-
larly-formed aggregates (known to be enhanced with chloro-
quine treatment [27]) that cannot later be taken up again
because of the presence of fucoidan; (2) the di¡erent time
points (6 h for ELISA, 24 h for aggregates) would result in
more aggregates at 24 h that could be blocked by fucoidan or
(3) the polyanionic compound fucoidan can block aggregate
formation by directly binding AL and inhibiting ¢bril forma-
tion.
Intracellular AL1^42 level was also increased upon co-incu-
bation with leupeptin which inhibited lysosomal cysteine pro-
teases. Our results were similar to those of Ard et al. [11] who
showed increased AL accumulation with 100 WM leupeptin.
Leupeptin is also an inhibitor for selective serine proteases.
Among studies which addressed extracellular AL degradation
by cell line conditioned medium (CM), leupeptin was shown
to inhibit extracellular serine proteases [28,29]. It is thus pos-
sible for leupeptin to increase the intracellular AL level (Fig.
3D) by inhibiting extracellular AL degradation and allowing
more AL uptake. However, this cannot account for our results
because (1) chloroquine, which inhibits intracellular degrada-
tion, had a similar e¡ect, (2) high concentrations of leupeptin
were required to increase intracellular AL, consistent with the
relatively slow leupeptin penetration into the cells, and (3) the
activity of secreted proteases was low in our experimental
conditions because the CM collected at 6 h had low AL-de-
grading activities (data not shown). Therefore, the contribu-
tion of extracellular serine proteases to AL degradation was
minor.
In conclusion, disruptions of the lysosomal system enhance
AL accumulation in microglia, consistent with data in SY5Y
neuroblastoma cells [7]. Since the lysosomal degradation of
AL1^42 is not as e¡ective as that of AL1^40, disruption of
lysosomal functions can retard the inherently slow AL1^42
degradation further which may serve as a seed for AL accu-
mulation and aggregation. Therefore, SAD could possibly be
potentiated by a gradual, age-related decline in lysosomal
functions [30^32] which could contribute to excessive AL ac-
cumulation and subsequent plaque development. Cathepsin
D, a lysosomal enzyme, has been reported to be a major
AL-degrading enzyme in brain [33,34]. Its upregulation in
AD and increased leakage outside the lysosome is evidence
for inadequate degradation and lysosomal disruption. Detec-
tion of AL known to be synthesized inside cells in AD is
limited by insu⁄cient sensitivity for measuring intracellular
AL. Therefore, failed attempts to detect intra-endosomal/lyso-
somal accumulations of AL may also relate to insu⁄cient
sensitivity, especially with AL1^40 and 42 antibodies. AL1^
40 and 42 epitopes may also be rapidly removed by carboxy-
peptidases such as lysosomal/endosomal cathepsin B. Another
explanation is that intralysosomal accumulation may induce
rapid cell death followed by the removal of the AL-containing
cell by phagocytosis, such as occurs during apoptosis. Finally,
the AL known to accumulate outside microglial processes
or on neuronal plasma membrane in Down’s [35] and in
early AD [36] may derive in part from AL exocytosed or
‘regurgitated’ [27] from endosomes accumulating AL.
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